I was drawn to medicine by the personal relationships I developed with my physicians in Iowa, where I grew up. I saw how they applied their unique skillsets within and outside the clinic setting, and I appreciated their approach to medicine as a personal calling to serve the community.
During my medical training, I found myself gravitating toward clinical work focused on children and their families. I loved the creativity required to connect with children and found great fulfillment working with parents to improve a child’s health. I also enjoyed the emphasis in pediatrics on supporting and caring for the family unit. I gained a strong appreciation for the importance of education in patient care and found great fulfillment working with children at various stages of their health.
As I progressed in my training, I became interested in many of the clinical issues that affect children. With my training in immunology, I felt particularly suited to the problems encountered within the pediatric population.
I am board-certified in both pediatrics and allergy and immunology. My special interests are in food allergy, oral immunotherapy and eosinophilic disorders. I have a strong commitment to addressing pediatric immune disorders through a coordinated approach to clinical care and translational research. I strive to provide excellent clinical care guided by evidence-based decision-making and focus on giving patients and families the opportunity to participate in their clinical care decisions. I also offer patients and families the opportunity to participate in research, as many desire an opportunity to contribute to the advancement of medical knowledge.
In my research, my colleagues and I are focused on developing less invasive testing for pediatric patients with eosinophilic esophagitis (EoE). Often, these patients are subjected to many invasive endoscopic evaluations, and there is a compelling need to develop less invasive biomarkers to evaluate EoE disease activity. My lab is trying to identify blood-based biomarkers that could reduce the need for many endoscopy procedures.
Oral immunotherapy is also an emerging treatment for children with food allergy. Unfortunately, few immunologic biomarkers can predict which patients will respond better to this therapy and track those patients having responses associated with long-term benefits. Our lab is trying to characterize early immunologic responses to oral immunotherapy to determine if these responses are associated with therapy outcomes and could be leveraged as biomarkers for predicting responses to therapy.
In my free time, I enjoy hiking, snowboarding and biking. In my late teens, I moved to Montana to pursue my undergraduate education and my love for the outdoors. I enjoy cooking and like to make different pasta dishes from scratch. I’m a family-focused individual and married with two children who are the inspiration behind what I do every day at work.
BS: Montana State University, Bozeman, MT, 2002.
MD/PhD: University of Iowa, Carver College of Medicine, Iowa City, IA, 2013.
Residency: Pediatrics, University of Iowa Children's Hospital, Iowa City, IA.
Pediatric allergy and immunology
Allergy and Immunology, Eosinophilic Disorders
Allergy and Immunology
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial. Journal of Allergy and Clinical Immunology. 2023; 152:1121-1130.e10.
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology. 2023; 8:803-815.
Food Allergy Characteristics Associated With Coexisting Eosinophilic Esophagitis in FARE Registry Participants. Journal of Allergy and Clinical Immunology: In Practice. 2023; 11:1509-1521.e6.
Breaking down the complex pathophysiology of eosinophilic esophagitis. Annals of Allergy, Asthma, and Immunology. 2023; 130:28-39.
Eosinophil-mediated suppression and anti-IL-5 enhancement of plasmacytoid dendritic cell interferon responses in asthma. Journal of Allergy and Clinical Immunology. 2022; 150:666-675.
Eosinophilic gastrointestinal diseases make a name for themselves: A new consensus statement with updated nomenclature. Journal of Allergy and Clinical Immunology. 2022; 150:291-293.
Targeted IL-4Rα blockade ameliorates refractory allergic eosinophilic inflammation in a patient with dysregulated TGF-β signaling due to ERBIN deficiency. Journal of Allergy and Clinical Immunology: In Practice. 2022; 10:1903-1906.
Aiolos regulates eosinophil migration into tissues. Mucosal Immunology. 2021; 14:1271-1281.
Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine. Current Allergy and Asthma Reports. 2020; 20:30.